Management of Hepatitis B Infection

  • Authors: Harry L. A. Janssen, MD, PhD; Milan J. Sonneveld, MD, PhD, MSc (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 5/25/18 (What's New)

Summary

  • HBV DNA levels after at least 24 weeks of peginterferon treatment provide a guide to likely outcome,[Hansen 2010] although the negative and positive predictive values are limited
  • Quantitative serum HBsAg levels may help to predict response to peginterferon in HBeAg-positive disease
    • European guidelines advise that HBeAg-positive patients who do not achieve HBsAg levels < 20,000 IU/mL (genotype B or C) or any decline in HBsAg levels from baseline (genotype A or D) by Week 12 of therapy may be considered for discontinuation of treatment (Table 11).[EASL HBV] At Week 24, any HBeAg-positive patient who has not achieved an HBsAg level < 20,000 IU/mL may also be considered for therapeutic stopping, regardless of genotype

Action required